Roche is trading at $58.95, up 3.17%, in a move consistent with a healthcare-sector rally; healthcare was the S&P 500’s best-performing sector as investors rotated away from technology stocks. - Roche’s potential $15 billion-plus Hansoh drug partnership was announced October 19, but available reporting does not directly link it to the ADR’s gain. - Roche said future German investment decisions were on hold; its planned Penzberg expansion is unaffected.